COVID-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group:After reviewing the criteria for entering the study and filling the consent form, patient will receive Tab Linagliptin 5mg(known as Melijent) once a day for 14 days
Sponsors
Gonabad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Consent to participate in research Diabetes Patients admitted to the ward with definite diagnosis of COVID-19 with PCR Disease severity of mild to moderate
Exclusion criteria
Exclusion criteria: Lack of interest to cooperate in research History of allergies to Linagliptin Taking interactive drugs at simultaneous use with linagliptin, according to FDA definition Adverse drug reactions occurrence
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peripheral capillary oxygen saturation. Timepoint: From the beginning of admission to the hospital and daily during admission. Method of measurement: Pulse oximeter.;Requirement of non-mechanical ventilation. Timepoint: From the beginning of admission to the hospital and discharge time. Method of measurement: Patient's file in hospital.;Requirement of mechanical ventilation. Timepoint: From the beginning of admission to the hospital and discharge time. Method of measurement: Patient's file in hospital.;Hospitalization duration. Timepoint: From the beginning of admission to the hospital and discharge time. Method of measurement: Patient's file in hospital.;Requirement of ICU. Timepoint: From the beginning of admission to the hospital and discharge time. Method of measurement: Patient's file in hospital.;Mortality. Timepoint: At the end of study. Method of measurement: Patient's file in hospital. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNahid Kheirabady
Gonabad University of Medical Sciences
Outcome results
None listed